Chk1 Inhibitor Induced DNA Damage Increases BFL1 and Decreases BIM but Does Not Protect Human Cancer Cell Lines From Chk1 Inhibitor-induced Apoptosis

Andrew J. Massey (a.massey@vermalis.com)
Vernalis (R&D) Ltd

Research Article

Keywords: Chk1, BFL1, MEK, DNA damage, kinase inhibitor

Posted Date: December 2nd, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1085750/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

V158411 is a potent, selective Chk1 inhibitor currently in pre-clinical development. We utilised RNAseq to evaluate the gene responses to V158411 treatment. BCL2A1 was highly upregulated in U2OS cells in response to V158411 treatment with BCL2A1 mRNA increased >400-fold in U2OS but not HT29 cells. Inhibitors of Chk1, Wee1 and topoisomerases but not other DNA damaging agents or inhibitors of ATR, ATM or DNA-PKcs increased BFL1 and decreased BIM protein. Increased BFL1 appeared limited to a subset of approximately 35% of U2OS cells. Out of 24 cell lines studied, U2OS cells were unique in being the only cell line with low basal BFL1 levels to be increased in response to DNA damage. Induction of BFL1 in U2OS cells appeared dependent on PI3K/AKT/mTOR/MEK pathway signalling but independent of NF-κB transcription factors. Inhibitors of MEK, mTOR and PI3K effectively blocked the increase in BFL1 following V15841 treatment. Increased BFL1 expression did not block apoptosis in U2OS cells in response to V158411 treatment and cells with high basal expression of BFL1 readily underwent caspase-dependent apoptosis following Chk1 inhibitor therapy. BFL1 induction in response to Chk1 inhibition appeared to be a rare event that was dependent on MEK/PI3K/AKT/mTOR signalling.

Introduction

DNA repair pathways have long been postulated as potential therapeutic targets for oncology therapeutics. The approval of numerous inhibitors of poly (ADP-ribose) polymerase (PARP; Olaparib, Rucaparib and Niraparib) for ovarian, fallopian tube and peritoneal cancer has validated this approach. One such potential area of interest is the DNA damage response (DDR) pathway with inhibitors of two of the central signalling kinases (Chk1 and ATR) currently in Phase 1 and 2 clinical trials.

DNA breaks arising from endogenous or exogenous DNA insults (including from cytotoxic chemotherapeutics) activate the DDR signalling pathway. DDR activation results in a range of cellular responses including DNA damage checkpoint activation and cell cycle arrest, initiation of DNA repair, regulation of transcription, and apoptosis. ATR and Chk1 kinases are key signalling components of the DDR response and are activated in response to DNA damage and replication stress. Chk1 is activated by ATR following the generation of ssDNA-dsDNA transitions whilst a second checkpoint kinase, Chk2, is activated by ATM in response to DNA breaks.

Numerous Chk1 inhibitors have entered Phase 1 and 2 clinical trials in combination with cytotoxic chemotherapy, ionising radiation or as single agents (recently reviewed in ). As monotherapy, Chk1 inhibitors generate S-phase DNA damage and mitotic catastrophe in human cancer cell lines. Tumour cells harbouring high levels of replicative stress or underlying DNA repair defects appear particularly hypersensitive to Chk1 inhibition. Whilst demonstrating some initial promise, no Chk1 inhibitors have so far managed to progress into Phase 3 registration trials with the majority terminating after Phase 1 trials. The reasons behind this are numerous and complex including (but not limited to) lack of efficacy, dose limiting toxicities (especially in combination), poor pharmaceutical properties (oral bioavailability, half-life), target patient population selection and drug combination selection.
V158411 is a potent, selective Chk1 inhibitor discovered using structure guided drug design\(^8\) that exhibits preclinical activity as a single agent\(^9\) and in combination with traditional cytotoxic chemotherapy. As a monotherapy, V158411 induces predominantly S-phase DNA damage and apoptotic as well as non-apoptotic cell death in a range of human cancer cell lines\(^9\). As part of an ongoing program evaluating the pharmacology of V158411 to guide clinical studies, we utilised RNAseq to evaluate the gene responses in a cell model that undergoes caspase-dependent apoptosis and a second model that did not following V158411 treatment. BFL1 was identified as one of the most upregulated genes following V158411 treatment and its role in cell death responses to Chk1 inhibition further profiled.

**Results**

**Chk1 inhibitors increase BFL1 expression in U2OS osteosarcoma cells**

To further understand the cellular response to Chk1 inhibition, the mRNA changes following Chk1 inhibition by V158411 in the human colon cancer cell line HT29 and osteosarcoma cell line U2OS were determined using RNAseq. In U2OS cells, but not HT29 cells, the anti-apoptotic Bcl-2 family member BCL2A1 (BFL1) (Fig. 1a) was highly upregulated (>400-fold). A small increase in Bcl-b (approximately 4-fold) but not in any of the other Bcl-2 family members was observed. Of the BH3-only genes, there was a small increase in NOXA and PUMA, and a small decrease in BIM. This increase in BCL2A1 mRNA appeared limited to a subset of U2OS cells with around 33% demonstrating increased BCL2A1 mRNA by imaging (Fig. 1b). These results were confirmed by western blotting (Fig. 1c) with the Wee1 inhibitor AZD1775 but not the ATR inhibitor VX-970 also increasing BFL1 protein levels. Increases in BFL1 protein by V158411 and AZD1775 were dose dependent (Fig. 1d) correlating closely with DNA damage induction and growth inhibition, and time dependent (Fig. 1e) with 24-hour treatment necessary to observe increases in BFL1 expression. Inhibition of Chk1 or Wee1 induced a time dependent decrease in BIM protein levels that mirrored the increase in BFL1 with decreased BIM observed after 24 hours of treatment (Fig. 1d). Chk1 and Wee1 inhibition increased NOXA slightly whilst Wee1i also increased PUMA expression. BID, BAD and BAX expression remained relatively unchanged.

BFL1 induction following Chk1 inhibition was not limited to V158411. Structurally distinct Chk1 inhibitors (LY2603618, MK8776 and PF-477736; Table S2, Table S3) increased BFL1 in U2OS cells (Fig. 2a) with BCL2A1 mRNA increases again limited to a subset of U2OS cells (Fig. 2b). Inhibitors of ATM (KU-60019) or DNA-PKcs (NU7746), two additional kinases in the DDR, did not activate BFL1 expression (Fig. 2a). This induction of BFL1 was not just limited to Chk1 inhibitors. Treatment of U2OS cells with topoisomerase inhibitors (camptothecin and etoposide) readily increased BFL1 expression (Fig. 2a, Fig. 2b) whilst other DNA damaging cytotoxic drugs (gemcitabine, hydroxyurea and cisplatin) did not. None of the agents induced a strong induction of Bcl-XL (Fig. 2c).
TNF-α, IL-1β or phorbol ester signalling increased BFL1 expression in U2OS cells

TNF-α, IL-1β and PMA all induced BFL1 expression with robust increases in BFL1 protein observed after 4-hour treatment with IL-1β and PMA and 24 hours with TNF-α (Fig. S1a). Bcl-XL remained unchanged following any of the treatments. Previous work has demonstrated that both PMA and etoposide induce BFL1 in the LNCaP prostate cancer cell line. Treatment of LNCaP cells with PMA for 4 hours induced BFL1 but by 24 hours the levels of BFL1 had returned to base line (Fig. S1b). In comparison, V158411 treatment of LNCaP cells for 6 to 72 hours had no effect on BFL1 protein levels (Fig. 3a). Likewise, treatment of LNCaP cells with AZD1775, LY2603618, gemcitabine, etoposide, camptothecin or cisplatin did not induce BFL1 protein levels (Fig. 3b). Similarly, PMA treatment of HeLa cells induced BFL1 and decreased BIM protein expression (Fig. 3c) but V158411, LY2603618, etoposide or camptothecin had no effect on BFL1 or BIM protein levels.

**BFL1 induction is a rare response in cancer cell lines to Chk1 inhibitor therapy**

A range of additional cancer cell lines (Table S4) were screened for BFL1 induction following treatment with V158411 (Fig. 3d, Fig. 3e). Of these, three cell lines (A2058, HL60 and PANC-1) exhibited higher basal expression of BFL1 and, of these, two (HL60 and PANC-1) had increased BFL1 expression following V158411 treatment (Fig. 3e). No discernible changes in Bcl-2, Bcl-XL or Mcl-1 were observed in cells following V158411 treatment. As observed with Chk1 inhibitors, no increase in BFL1 was observed in MES-SA or SJSA-1 cells treated with gemcitabine, camptothecin, etoposide or cisplatin (Fig. S1c) or HT29, MDA-MB-231 or SKOV3 cells treated with gemcitabine or camptothecin (Fig. S1d). No induction of Bcl-XL was observed. However, in the PANC-1 cells, V158411 and LY2603618 strongly induced BFL1, and all of the DNA damaging agents moderately induced BFL1 (Fig. S1e).

**Chk1i-induced BFL1 expression appeared independent of NF-κB transcription factor**

To further understand the mechanism by which DDR or topoisomerase inhibitors increase BFL1 expression, we evaluated the effects of these molecules on a NF-κB transcription factor signalling. NF-κB is the transcription factor most associated with BFL1 induction. TNF-α, IL-1β and all induced BFL1 expression with robust increases in BFL1 protein observed after 4-hour treatment with IL-1β and PMA and 24 hours with TNF-α (Fig. S1a). This increase in BFL1 appeared NF-κB dependent as PMA, TNF-α or IL-1β all induced an NF-κB reporter stably expressed in U2OS cells (Fig. 4a) and treatment of U2OS cells with TNF-α resulted in clear nuclear translocation of p65 (Fig. 4b) and, to a lesser extent, phosphor-p65, c-Rel and RelB (data not shown). Chk1, Wee1 or topoisomerase inhibitors did not induce an NF-κB reporter stably expressed in U2OS cells (Fig. 4a). Using single-cell immunofluorescence, V158411 treatment increased the apparent nuclear translocation of p65, phosphor-p65 and p50 forms of NF-κB. However, on closer inspection of the single cell data, there appeared to be noticeable decreases in nuclear NF-κB in a...
fraction of the treated cells (Fig. 4c) with the increased nuclear NF-κB correlating with DNA condensation and therefore cell death. These immunofluorescence observations were confirmed by western blotting (Fig. 4d) with no distinct changes in NF-κB signalling detected in U2OS cells treated with V158411.

**MEK, mTOR/PI3K or pan-TK kinase inhibitors abrogate V158411 induced BFL1 expression and restore BIM expression**

PMA, a potent activator of PKC, increased BFL1 and decreased BIM expression in U2OS cells. Inhibition of PKC with sotrastaurin reversed these effects returning BFL1 and BIM protein to basal levels (Fig. S2a). In comparison, sotrastaurin had little effect on BFL1 induction or BIM reduction by V158411. At the concentration used, sotrastaurin had no effect of U2OS cell viability (Fig. S2b).

A range of kinase inhibitors (Table S5) were therefore screened for potential to inhibit the induction of BFL1 by V158411. From this, the MEK inhibitor trametinib, mTOR inhibitor AZD8055, PI3K/mTOR inhibitor dactolisib, the PI3K inhibitor pictilisib, and the pan-tyrosine kinase inhibitors ponatinib, crizotinib and dovitinib all blocked BFL1 induction by V158411 (Fig. 5a). IC\textsubscript{50} values for inhibition of BFL1-induction ranged from 41 nM to 1.6 µM (Fig. 5b, Table S5). None of the kinase inhibitors dramatically affected the induction of DNA damage (as measured by increase in nuclear γH2AX) by V158411 (data not shown). Their effects on U2OS cell proliferation are highlighted in Table S5. In addition to reducing BFL1 induction by V158411, dactilosib, AZD8055, ponatinib and trametinib blocked the reduction in BIM1 (Fig. 5c). As would be predicted from their mechanisms of action, trametinib inhibited the phosphorylation of ERK, and dactilosib and AZD8055 reduced AKT phosphorylation.

**Inhibition of Chk1 increases AKT and ERK phosphorylation in U2OS cells**

Inhibition of Chk1 in U2OS cells increased AKT and ERK phosphorylation (Fig. 6b). These changes appeared time (Fig. 6b) and dose dependent (Fig. 6c) with kinetics that appeared similar to the induction of BFL1 with 24-hour treatment necessary to increase pAKT. These results were confirmed by single cell immunofluorescent imaging with V158411 treatment increasing the fraction of cells staining positive for pAKT and pERK (Fig. 6d). This increase in pAKT occurred dose dependently following V158411 and AZD1775 treatment (Fig. 6e) and correlated with increased V158411 DNA damage (as measured by increased nuclear γH2AX, Fig. S3a).

Increased pAKT was only observed in U2OS cells treated with Chk1 inhibitors and not the topoisomerase inhibitors camptotheacin and etoposide (Fig. 6f, Fig. 6g, Fig. S3b). pERK was strongly induced by DNA damaging agents including gemcitabine, which did not induce BFL1 (Fig. 6f) and to a greater extent than that induced by V158411. Increased AKT and ERK phosphorylation in response to Chk1 inhibitor treatment was observed in other cell lines. Increased pAKT was observed in SKOV3 cells treated with V158411 (Fig. S3c) whilst increased pERK was observed in SJSA-1 cells (Fig. S3d).
Inhibition of BFL1 induction by Trametinib was not limited to V158411

Trametinib appeared the most consistent kinase inhibitor in preventing BFL1 induction in U2OS cells by Chk1, Wee1 and topoisomerase inhibitors. BFL1 induction by V158411, LY2603618, AZD1775, camptothecin and etoposide were all inhibited by trametinib and dactilosib (Fig. 7a). In comparison, AZD8055 failed to block BFL1 induction by AZD1775 and, ponatinib, BFL1 induction by camptothecin. As well as blocking BFL1 induction, trametinib reversed the downregulation of BIM in U2OS cells treated with V158411, LY2603618, AZD1775, camptothecin or etoposide (Fig. 7b). These effects were not limited to U2OS cells. In PANC-1 cells, trametinib inhibited BFL1 induction and BIM reduction following V158411, LY2603618, AZD1775, camptothecin or etoposide treatment (Fig. 7c). Interestingly, trametinib reduced the high basal expression levels of BFL1 in the DMSO treated control PANC-1 cells.

BFL1 induction does not decrease Chk1 inhibitor induced apoptosis

BFL1 is a member of the Bcl-2 family of anti-apoptotic proteins. In the A2058 cell line, which exhibits high basal levels of BFL1, V158411 induced high levels of apoptosis with around 70% staining positive for cleaved capsase-3/7 after 48 hours (Fig. 8a). We have previously observed significant levels of apoptosis in the HL60, another cell line with high basal BFL1, after V158411 treatment.14 Likewise, U2OS readily underwent caspase-3/7 dependent apoptosis after V158411 treatment with around 63 and 67% of cells cleaved caspase-3/7 positive after 48 and 72 hours (Fig. 8a). In the cell lines where little apoptosis was observed (MES-SA and SJSA-1), V158411 still inhibited the proliferation of these cells (Fig. 8b). Given that BFL1 expression was upregulated in a subset of around 30% of U2OS cells, we examined BFL1 expression in attached (live) versus detached (dead) cells after V158411 treatment. At the earliest time point (48 hours), BFL1 was only detected in the adherent cells suggestive of some protective effect from V158411-induced apoptosis. However, after 72-hour treatment with V158411, significant amounts of BFL1 was detected in the detached as well as the attached cell populations (Fig. 8c). These detached cells were apoptotic as determined by the detection of cleaved lamin A and cleaved PARP suggesting that these cells were still able to undergo caspase-dependent apoptosis despite the increased expression of BFL1. In the A2058 cells a similar pattern of BFL1 expression was observed with the detached, cleaved lamin A / cleaved PARP positive population containing high levels of BFL1 (Fig. 8d).

The effects of AZD8055 and trametinib, two kinase inhibitors that blocked BFL1 induction by V158411, on V158411 induced apoptosis and cell death were evaluated. In U2OS cells, AZD8055 inhibited the induction of apoptosis by V158411 by 2-3 fold (Fig. 8e). This actually translated into a greater reduction in cell proliferation compared to V158411 but not cell death. In comparison, trametinib increased the amount of V158411-induced apoptosis especially at the early time point of 24 hours and the lower concentration of 1xGI<sub>50</sub> (Fig. 8f). This translated into increased cell death at this concentration. However, at 3xGI<sub>50</sub> trametinib did not dramatically increase the amount of apoptosis or cell death above that
observed with V158411 alone. The results with trametinib were somewhat complicated by the fact that trametinib as a single agent appeared to induce caspase-3/7 cleavage without any significant effects on cell proliferation or death. Finally, trametinib failed to potentiate cell killing by V158411 in PANC-1 cells. In the absence of trametinib, the V158411 GI_{50} was 4.2 ± 0.8 µM compared to 4.1 ± 1.5 µM in combination with 1 µM trametinib.

**Discussion**

Numerous Chk1 inhibitors have been described to date and demonstrate exciting anti-tumour efficacy as single agents, in combination with cytotoxic chemotherapy, and in combination with novel targeted therapies (such as PARP inhibitors). Despite these initially exciting pre-clinical results, no inhibitors have yet to progress beyond Phase 2 into Phase 3 registration trials with the majority terminating after Phase 1 \cite{6,15,16}. The reasons behind this are numerous and complex including (but not limited to) lack of efficacy, dose limiting toxicities (especially in combination), poor pharmaceutical properties (oral bioavailability, half-life), target patient population selection and drug combination selection.

To further evaluate the clinical potential of our own Chk1 inhibitor, V158411 \cite{8}, we utilised RNAseq analysis of V158411 treated cancer cells to evaluate the genome wide changes to inhibitor treatment. One of the most upregulated genes in response to V158411 treatment in the U2OS osteosarcoma cell line was BCL2A1 (BFL1). BFL1 is a member of the Bcl-2 family of antiapoptotic proteins that also includes the much wider studied Bcl-2, Mcl-1 and Bcl-XL members \cite{17,18}. BFL1 has been implicated in the development of lymphomas and leukaemia's \cite{19–21}, and increased BCL2A1 is associated with resistance to the clinically approved Bcl-2 inhibitor Venetoclax \cite{22,23}. Upregulated BCL2A1 / BFL1 has been identified in melanoma \cite{24,25} where it confers resistance to Braf inhibitors. Like the other members of the Bcl-2 family of proteins, BFL1 binds to pro-apoptotic Bcl-2 proteins (such as BAK and BAX) and pro-apoptotic BH3-only proteins (such as tBID, BIM, PUMA and NOXA) thereby preventing mitochondrial membrane permeability, cytochrome c release and caspase activation in response to apoptotic stimuli.

Chk1 inhibition by V158411 induces replication stress and DNA damage in a wide range of human cancer cell lines of differing tumour types \cite{9,14,26}. Out of the 24 cell lines studied, U2OS cells were the only cell line with low basal BFL1 protein levels that were increased by V158411. The increase in BCL2A1 mRNA expression in response to Chk1 inhibitor induced DNA damage appeared restricted to a subset of around 30-40% of the U2OS cells. Three additional osteosarcoma cell lines were evaluated (HOSTE85, SAOS-2 and SJSA-1) but did not induce BFL1 protein in response to V158411-induced DNA damage. Increases were also observed in the HL60 myeloid leukaemia, and PANC-1 pancreatic cancer cell line but these two cell lines had high basal BFL1 expression levels. The reason why U2OS, HL60 and PANC-1 cells were sensitive to BFL1 induction by V158411 was not immediately apparent. The cells all come from diverse tissue types (bone, blood and pancreas respectively), have no obvious common driver mutations, and vary widely in their sensitivity to growth inhibition by V158411 (0.82, 0.21 and 8.0 µM respectively).
Further work is ongoing to understand these differences in BFL1 induction response between different cell lines.

The increase in BCL2A1 / BFL1 in U2OS cells was not limited to V158411 but was also induced by other Chk1 inhibitors, the Wee1 inhibitor AZD1775 and topoisomerase inhibitors. The topoisomerase inhibitors etoposide and camptothecin have both previously been demonstrated to increase BFL1. However, other inducers of DNA damage such as the cytotoxic chemotherapy drugs gemcitabine, hydroxyurea and cisplatin, and inhibitors of the DNA damage response proteins ATR, ATM and DNA-PKcs did not increase BFL1 expression. The fact that not all DNA damage resulted in BFL1 induction suggests that the cells are responding to either a specific kind of DNA damage and/or DNA damage induced at a specific point in the cell cycle.

In addition to increasing BCL2A1, V158411 increased BCL2L10 (Bcl-b) mRNA though to a much lesser extent (5.8-fold) than BCL2A1 (444-fold). Coupled to this was a decrease in BIM mRNA and protein levels. The mechanism by which BCL2A1 mRNA was increased in U2OS cells by V158411 so far appears unclear. Previous studies have demonstrated NF-κB as a significant transcriptional inducer of BCL2A1. NF-κB also upregulates Bcl-XL with the two proteins often co-induced by NF-κB activating stimuli. Here we observed only an increase in BFL1 and not Bcl-XL and found no evidence for NF-κB activation in response to Chk1i, Wee1i or topoisomerasei treatment in U2OS cells. In melanoma cells, BCL2A1 is upregulated via MITF but as U2OS are osteosarcoma cells, it would appear unlikely that MITF is responsible in this cell line.

In prostate cancer, BCL2A1 was induced by both PMA and etoposide via a PKCδ-dependent mechanism. V158411 induced BCL2A1 via a different mechanism as the PKC inhibitor sotrastaurin inhibited BFL1 induction by PMA but not that by V158411. AKT and ERK phosphorylation was increased in V158411 treated U2OS cells and the induction of BFL1 by V158411 appeared dependent on signalling through the MEK/PI3K/AKT/mTOR dependent pathways. Inhibitors targeting these pathways effectively blocked BFL1 induction not only by Chk1 inhibitors but also by topoisomerase inhibitors as well. The MEK inhibitor Trametinib appeared the most active inhibitor of BFL1 induction by Chk1 or topoisomerase inhibitors. There is limited literature to date linking BCL2A1 with either the MEK or PI3K/AKT pathways. BCL2A1 has been demonstrated to be regulated by PI3K/AKT to control neutrophil survival and homeostasis and eosinophil adhesion to IMR-32 cells increased BCL2A1 in a PI3K-MEK/ERK-NF-κB dependent mechanism to protect against neuronal induced apoptosis. Clear synergy between Chk1 inhibitors and mTOR inhibitors and MEK inhibitors has been demonstrated with potentially the control of anti-apoptotic protein expression contributing to this.

A very recent study has demonstrated that BFL1 (BCL2A1) and Bcl-b (BCL2L10) are stabilised by Ubiquilin4 (UBQLN4). UBQLN4 is a substrate of ATM and is phosphorylated (and thereby activated) in response to ATM-activating DNA damage including that induced by the topoisomerase inhibitor camptothecin. BCL2A1 and BCL2L10 stabilisation by UBQLN4 reduced apoptosis in response to DNA
damage in a mesothelioma cell model. Chk1 and Wee1 inhibitors activate ATM \(^9,39,40\). In this study, the induction of BFL1 protein by Chk1i, Wee1i and topoisomerasei-induced DNA damage appears to be via an increase in BCL2A1 mRNA with BCL2A1 mRNA increased over 400-fold following V158411 treatment. BCL2L10 was also increased by V158411 but to a much lesser extent (around 5.8-fold). Likewise, inhibition of ATM with KU-60019 did not block increased BFL1 expression following V158411 treatment. However, increased protein stability through UBQLN4-induced stabilisation may contribute to increased BFL1 protein levels through reduced protein turnover.

Whilst BFL1 was induced following V158411-induced DNA damage in U2OS cells, it did not appear to block apoptosis in these cells with high levels of BFL1 protein observed in apoptotic cells. Likewise cells with high basal levels of BFL1 (namely A2058 and HL60 \(^{14}\)) appeared to readily undergo caspase dependent apoptosis in response to Chk1 inhibition. Blocking the V158411 induced induction of BFL1 with Trametinib did not increase the fraction of U2OS cells undergoing caspase-dependent apoptosis. There was still a subset of around 30-40% of the cells that were resistant to V158411 induced apoptosis. This is in direct contrast to studies with inhibitors of other Bcl-2 family proteins. The Bcl-2 inhibitor venetoclax (ABT-199) increased the fraction of apoptotic AML cells when combined with a Chk1 inhibitor \(^{41}\) whilst the Bcl-2/Bcl-XL inhibitor navitoclax sensitised pancreatic cancer cells to apoptosis induced by the Chk1 inhibitor prexasertib \(^{42}\).

In conclusion, DNA damage induced by Chk1, Wee1 or topoisomerase inhibitors increased BFL1 expression and downregulated BIM via an PI3K/AKT/MEK dependent (and NF-κB independent) pathway in a subset of U2OS cells. This increase in BFL1 appeared to be an attempt by the cells to block DNA damage induced apoptosis. This attempt to inhibit apoptosis was ultimately futile as the cells still underwent apoptosis. Further work is ongoing to further understand the mechanism of BFL1 induction in this cell model.

**Materials And Methods**

**Cell lines and cell culture**

Cell lines were purchased from the American Type Culture Collection (ATCC, LGC Standards, Teddington, UK) or the European Collection of Authenticated Cell Cultures (ECACC, Public Health England, Salisbury, UK), established as a low passage cell bank and then routinely passaged in our laboratory for less than 3 months after resuscitation. These were routinely cultured in media containing 10% FCS and 1% penicillin/streptomycin (complete media) at 37°C in a normal humidified atmosphere supplemented with 5% CO\(_2\). Cells were authenticated by STR profiling (LGC Standards) and routinely checked for mycoplasma contamination.

**Compounds**
V158411 was from Vernalis (R&D) Ltd (Cambridge, UK). The other kinase inhibitors were purchased from Selleckchem (Houston, USA). All were prepared as 20 mM DMSO stocks. Cytotoxics were purchased from the indicated suppliers and prepared as described: gemcitabine (Apin Chemicals Ltd, Oxford, UK), 20mM in H₂O; camptothecin (LC Laboratories, Woburn, MA), 5mM in DMSO; etoposide (LC Laboratories), 50 mM in DMSO; cisplatin (Selleckchem), 3.33 mM in 1% NaCl; and hydroxyurea (Sigma Aldrich, Poole, UK), 0.5 M in H₂O. TNF-α, IL-1β and IFN-γ were purchased from R&D Systems (Abingdon, UK), and PMA and LPS from Invivogen (Toulouse, France).

Antibodies

The antibodies used in this study and the dilutions used are listed in Table S1.

Immunoblotting

Cells were washed once with PBS and lysed in RIPA buffer containing protease and phosphatase inhibitor cocktails (Sigma). Protein concentration was determined using a BCA kit (Thermo Fisher Scientific, Hemel Hempstead, UK). Equal amounts of lysate were separated by SDS-PAGE and western blot analysis conducted using the antibodies indicated above. ImageJ software (NIH) was used for densitometric analysis.

Single Cell Immunofluorescent Imaging

This was conducted as previously described ⁹ using the antibodies listed in Table S1.

Single Cell mRNA Expression Imaging

Single cell mRNA expression was determined using a ViewRNA Cell Plus assay kit (Thermo Fisher Scientific) with probes against BCL2A1 (BFL1, VA6-20602-VCP, AF647) and B2M (Beta-2-Microglobulin, VA4-13460-VCP, AF488) according to the manufacturer's instructions. Cells were imaged with an Operetta high content imager (Perkin Elmer, Sear Green, UK) using a 40x high NA objective. Fluorescent spots were quantified using Harmony software (Perkin Elmer).

NF-κB Reporter Cell Line Generation

U2OS cells were transfected with a NF-κB-RE-NanoLuc reporter plasmid (N1111, Promega) and a stable cell line generated by Hygromycin B selection (Invitrogen). The reporter contains a PEST destabilized version of the NanoLuc gene (NlucP). NlucP reporter activity was determined using a Nano-Glo luciferase assay system (N1110, Promega) and a Victor Nivo plate reader (Perkin Elmer).

RNAseq expression analysis

RNAseq analysis was conducted by Lexogen (Vienna, Austria). RNA was extracted from treated cells using a SPLIT kit, an RNA library prepared using a QuantSeq 3’ mRNA-Seq Library Prep Kit FWD from Illumina and then sequenced using NextSeq 75 cycle high output sequencing with v2 chemistry on a
HiSeq 2500 platform (Illumina, San Diego, CA). Data was analysed using a QuantSeq data analysis pipeline.

Cell Proliferation, Cytotoxicity and Apoptosis Assay

Cell proliferation was determined using either sulphorhodamine B staining or CellTiter Glo (Promega). Live cell imaging experiments were conducted on an Operetta high content imager essentially as previously described 9.

Declarations

Acknowledgements

We thank Emer Murphy and Theophile Regnier for technical help in the preparation of this manuscript.

Author Contributions

A.J.M. performed study concept and design; development of methodology; acquisition, analysis and interpretation of data, statistical analysis, writing, review and revision of the paper.

Conflict of Interest

A.J.M is an employee of Vernalis (R&D) Ltd.

Ethics Statement

No ethical approval was required for this study.

Funding Statement

This work was funded by Vernalis (R&D) Ltd.

Data Availability Statement

All data is available from the corresponding author upon reasonable request.

Competing Interests

AJM is an employee of Vernalis (R&D) Ltd and this work was funded by Vernalis (R&D) Ltd.

References

1. Pilie, P. G., Gay, C. M., Byers, L. A., O'Connor, M. J. & Yap, T. A. PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers. Clin.Cancer Res. 25, 3759-3771 (2019).
2. Yap, T. A., Plummer, R., Azad, N. S. & Hellday, T. The DNA Damaging Revolution: PARP Inhibitors and Beyond. *Am.Soc.Clin.Oncol.Educ.Book.* **39**, 185-195 (2019).

3. Forment, J. V. & O’Connor, M. J. Targeting the replication stress response in cancer. *Pharmacol.Ther.* **188**, 155-167, doi:https://doi.org/10.1016/j.pharmthera.2018.03.005 (2018).

4. Niida, H., Katsuno, Y., Banerjee, B., Hande, M. P. & Nakanishi, M. Specific role of Chk1 phosphorylations in cell survival and checkpoint activation. *Mol.Cell Biol.* **27**, 2572-2581 (2007).

5. Tapia-Alveal, C., Calonge, T. M. & O’Connell, M. J. Regulation of chk1. *Cell Div.* **4**, 8 (2009).

6. Dent, P. Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer. *Expert.Opin.Investig.Drugs* **28**, 1095-1100 (2019).

7. Pilie, P. G., Tang, C., Mills, G. B. & Yap, T. A. State-of-the-art strategies for targeting the DNA damage response in cancer. *Nat.Rev.Clin.Oncol.* **16**, 81-104, doi:https://doi.org/10.1038/s41571-018-0114-z (2019).

8. Massey, A. J. *et al.* Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design. *Oncotarget.* **6**, 35797-35812, doi:https://doi.org/10.18632/oncotarget.5929 (2015).

9. Wayne, J., Brooks, T. & Massey, A. J. Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase. *Oncotarget.* **7**, 85033-85048, doi:https://doi.org/10.18632/oncotarget.13119 (2016).

10. Caino, M. C., von Burstin, V. A., Lopez-Haber, C. & Kazanietz, M. G. Differential regulation of gene expression by protein kinase C isozymes as determined by genome-wide expression analysis. *J Biol Chem* **286**, 11254-11264, doi:10.1074/jbc.M110.194332 (2011).

11. Kim, M. K. *et al.* The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1. *Mol Cancer* **10**, 98, doi:10.1186/1476-4598-10-98 (2011).

12. Cheng, Q., Lee, H. H., Li, Y., Parks, T. P. & Cheng, G. Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition. *Oncogene* **19**, 4936-4940, doi:10.1038/sj.onc.1203861 (2000).

13. Zong, W. X., Edelstein, L. C., Chen, C., Bash, J. & Gélinas, C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. *Genes Dev* **13**, 382-387, doi:10.1101/gad.13.4.382 (1999).

14. Bryant, C., Scriven, K. & Massey, A. J. Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells. *Mol.Cancer* **13**, 147, doi:https://doi.org/10.1186/1476-4598-13-147 (2014).

15. Neizer-Ashun, F. & Bhattacharya, R. Reality CHEK: Understanding the biology and clinical potential of CHK1. *Cancer Lett* **497**, 202-211, doi:10.1016/j.canlet.2020.09.016 (2021).

16. Gorecki, L., Andrš, M. & Korabecný, J. Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer. *Cancers (Basel)* **13**, doi:10.3390/cancers13040795 (2021).
17. Vogler, M. BCL2A1: the underdog in the BCL2 family. Cell Death Differ 19, 67-74, doi:10.1038/cdd.2011.158 (2012).

18. Li, X., Dou, J., You, Q. & Jiang, Z. Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy. Eur J Med Chem 220, 113539, doi:10.1016/j.ejmech.2021.113539 (2021).

19. Piva, R. et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest 116, 3171-3182, doi:10.1172/jci29401 (2006).

20. Beverly, L. J. & Varmus, H. E. MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene 28, 1274-1279, doi:10.1038/onc.2008.466 (2009).

21. Ottina, E. et al. Targeting antiapoptotic A1/Bfl-1 by in vivo RNAi reveals multiple roles in leukocyte development in mice. Blood 119, 6032-6042, doi:10.1182/blood-2011-12-399089 (2012).

22. Bisaillon, R. et al. Genetic characterization of ABT-199 sensitivity in human AML. Leukemia 34, 63-74, doi:10.1038/s41375-019-0485-x (2020).

23. Zhang, H. et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer 1, 826-839, doi:10.1038/s43018-020-0103-x (2020).

24. Hind, C. K. et al. Role of the pro-survival molecule Bfl-1 in melanoma. Int J Biochem Cell Biol 59, 94-102, doi:10.1016/j.biocel.2014.11.015 (2015).

25. Haq, R. et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 110, 4321-4326, doi:10.1073/pnas.1205575110 (2013).

26. Bryant, C., Rawlinson, R. & Massey, A. J. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. Biology Cancer 14, 570 (2014).

27. Ullmannová, V. & Haskovec, C. Gene expression during camptothecin-induced apoptosis in human myeloid leukemia cell line ML-2. Neoplasma 51, 175-180 (2004).

28. Chen, C., Edelstein, L. C. & Gélinas, C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 20, 2687-2695, doi:10.1128/mcb.20.8.2687-2695.2000 (2000).

29. Lee, H. H., Dadgostar, H., Cheng, Q., Shu, J. & Cheng, G. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci U S A 96, 9136-9141, doi:10.1073/pnas.96.16.9136 (1999).

30. Vier, J., Groth, M., Sochalska, M. & Kirschnek, S. The anti-apoptotic Bcl-2 family protein A1/Bfl-1 regulates neutrophil survival and homeostasis and is controlled via PI3K and JAK/STAT signaling. Cell Death Dis 5, e2103, doi:10.1038/cddis.2016.23 (2016).

31. Morgan, R. K. et al. Eosinophil adhesion to cholinergic IMR-32 cells protects against induced neuronal apoptosis. J Immunol 173, 5963-5970, doi:10.4049/jimmunol.173.10.5963 (2004).

32. Massey, A. J. et al. mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition. Mol. Oncol. 10, 101-112 (2016).
33. Huang, T. T. et al. Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer. *Cancer Res* **80**, 5380-5392, doi:10.1158/0008-5472.Can-20-1439 (2020).

34. Song, X. et al. Synergistic targeting of CHK1 and mTOR in MYC-driven tumors. *Carcinogenesis* **42**, 448-460, doi:10.1093/carcin/bgaa119 (2021).

35. Tang, Y., Dai, Y., Grant, S. & Dent, P. Enhancing CHK1 inhibitor lethality in glioblastoma. *Cancer Biol. Ther.* **13**, 379-388 (2012).

36. Dai, Y. et al. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. *Blood* **112**, 2439-2449 (2008).

37. Pei, X. Y. et al. Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. *Blood* **118**, 5189-5200 (2011).

38. Liu, F. et al. UBQLN4 is an ATM substrate that stabilizes the anti-apoptotic proteins BCL2A1 and BCL2L10 in mesothelioma. *Mol Oncol*, doi:10.1002/1878-0261.13058 (2021).

39. Wang, F. Z. et al. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells. *Apoptosis*. **19**, 1389-1398 (2014).

40. Jin, M. H. et al. Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer. *Cancer Res Treat* **52**, 149-166, doi:10.4143/crt.2019.183 (2020).

41. Zhao, J. et al. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. *Oncotarget* **7**, 34785-34799, doi:10.18632/oncotarget.9185 (2016).

42. Morimoto, Y. et al. Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2. *Mol Cell Biochem* **472**, 187-198, doi:10.1007/s11010-020-03796-6 (2020).

**Figures**
Figure 1

Inhibition of Chk1 increases BFL1 and decreases BIM expression in U2OS cells. (a) HT29 or U2OS cells were treated with 1x γH2AX EC50 of V158411 for 24 hours and gene expression determined by RNAseq analysis. Values are the mean of 2 independent replicates. (b) U2OS cells were treated with 3x GI50 of V158411 for 24 hours and BCL2A1 (BFL1) mRNA expression determined using ViewRNA technology. Each point represents an individual cell. Data is derived from 3 independent wells. U2OS cells were treated with (c) 3x GI50 for the indicated times, (d) 3x GI50 for 1 – 48 hours or (e) 0.1 – 3x GI50 for 48 hours and protein expression determined by western blotting.

Figure 2
Structurally diverse Chk1 inhibitors or topoisomerase inhibitors induce BFL1 mRNA and protein expression in U2OS cells. (a) U2OS cells were treated with the indicated compounds (see Table S2 for list of abbreviations and Table S3 for GI50 values) for 48 hours. (b) U2OS cells were treated with 3x GI50 for 24 hours and BCL2A1 (BFL1) mRNA expression determined using ViewRNA technology. Each point represents an individual cell. Data is derived from 3 independent wells. (c) U2OS cells were treated with 1x GI50 of the indicated compounds for 48 hours.

Figure 3

Increased BFL1 expression following Chk1i was observed only in a subset of human cancer cell lines. (a) LNCaP cells were treated with 1 or 3x GI50 of the indicated compounds for 48 hours. (b) HeLa cells were treated with 100 ng/mL PMA for 4 hours, or 1 or 3x GI50 of the indicated compounds for 48 hours. (c) Cells were treated with 0-3x GI50 of V158411 for 48 hours. (d) Cells were treated with 3x GI50 of V158411 or AZD1775 for 48 hours. (e) Cells were treated with 0-3x GI50 of V158411 for 48 hours.
Figure 4

Chk1i-induced BFL1 expression appeared independent of NF-κB transcription factors. (a) U2OS-NF-κB-RE reporter cells were treated with 3x GI50 V158411, AZD1775, LY2603618, camptothecin or etoposide, or 100 ng/mL PMA, 30 ng/mL TNF-α or 30 ng/mL IL-1β for 4 – 48 hours. Values are the mean ± SD of 3 replicates. (b) U2OS cells were treated with 10 ng/mL TNF-α for 30 minutes and the NF-κB nuclear intensity determined by single cell IF. (c) U2OS cells were treated with 1 or 3x GI50 V158411 for 24 hours.
and the nuclear intensity of the indicated proteins determined by single cell IF. Each point represents an individual cell. Data is derived from 3 independent wells. (d) U2OS cells were treated with 3x GI50 V158411 for 24 hours.

Figure 5

MEK, mTOR/PI3K or pan-TK kinase inhibitors abrogate V158411 induced BFL1 expression and restore BIM expression. (a) U2OS cells were treated with the indicated kinase inhibitors (see Table S5 for
concentrations) in combination with 3x GI50 V158411 for 24 hours. (b) U2OS cells were treated with the indicated concentrations of kinase inhibitors in combination with 3x GI50 V158411 for 24 hours. (c) U2OS cells were treated with 0.3 µM kinase inhibitor plus 3x GI50 V158411 for 24 hours.

**Figure 6**

Chk1i and Wee1i increase AKT and ERK phosphorylation in U2OS cells. U2OS cells were treated with (a) 1x or 3x GI50 for 48 hours, (b) 3x GI50 for 1 – 48 hours, or (c) 0.1 – 3x GI50 for 48 hours. Protein expression was determined by western blotting. U2OS cells were treated with (d) 0 – 3x GI50 V158411 for 24 hours, (e) 0.1 – 3x GI50 V158411 or AZD1775 for 24 hours. Protein expression determined by single cell IF. Values are the mean of 3 independent wells ± SD. (f) and (g) U2OS cells were treated with 1 or 3x GI50 of compound for 24 hours. Expression of indicated proteins was determined by single cell immunofluorescent imaging. Values are the mean of 3 independent wells ± SD.

![Figure 6](image)

**Figure 7**

MEK, mTOR/PI3K or pan-TK kinase inhibitors abrogate Chk1i, Wee1i or Topoisomerase inhibitor induced BFL1 expression and restore BIM protein levels. (a) U2OS cells were treated with 0.3 µM kinase inhibitor in combination with 3x GI50 (Table S3) of the other indicated agents for 24 hours. (b) U2OS cells were treated with 0.3 µM Trametinib in combination with 3x GI50 of the other indicated agents for 24 hours. (c) PANC-1 cells were treated with 0.3 µM Trametinib in combination with 3x GI50 of the other indicated agents for 24 hours.

![Figure 7](image)
Figure 8

Chk1 inhibition induces apoptosis despite increased BFL1 expression. (a) Cleaved Caspase 3/7 (CC3/7) and (b) total cells were determined using high content live cell imaging following treatment with 3x GI50 V518411. Values are the mean of 3 wells ± SD. (c) U2OS cells were treated with 3x GI50 V158411. At the indicated time points, attached (A) and detached (D) cells were separately lysed. Experiment was performed in triplicate and a representative experiment shown. (d) Cells were treated with 3x GI50
V518411 for 72 hours and analysed as in (c) (C, untreated control cells). U2OS cells were treated with 1 or 3x GI50 V58411 (V411) in combination with (e) 0.3 μM AZD8055 (AZD) or (f) 0.3 μM Trametinib (Tram). Apoptotic nuclei and total cell number were determined using live cell high content imaging. Values are the mean of 3 independent wells ± SD.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- [MasseyBFLInductionbyChk1iSI.pdf](MasseyBFLInductionbyChk1iSI.pdf)